In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
In this Blood Cancer Discovery study, Teclistamab-cqyv led to clinically meaningful responses in patients with heavily pretreated multiple myeloma who would have been ineligible for the MajesTEC-1 trial. Check it out: buff.ly/wMmq7EK
From leading the American Cancer Society to advancing @parkerici.bsky.social, her work exemplifies bold science and strategic leadership.
highlighting inequities in #oncology testing that exist today, in 2024, due to racial & access barriers was eye-opening. #MedSky #CME
www.medlearninggroup.com/cme-programm...
highlighting inequities in #oncology testing that exist today, in 2024, due to racial & access barriers was eye-opening. #MedSky #CME
www.medlearninggroup.com/cme-programm...